publication . Article . 2004

Clinical Pharmacology of Novel Selective COX-2 Inhibitors

S. Tacconelli; Paola Patrignani; Marta L. Capone;
Open Access
  • Published: 01 Feb 2004
Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed. They have the potential advantage to spare COX-1 activity, thus reducing gastrointestinal toxicity, even when administered at high doses to improve efficacy. They are characterized by different pharmacodynamic and pharmacokinetics features. The higher biochemical selectivity of valdecoxib than celecoxib, evidenced in vitro, may be clinically relevant leading to an improved gastrointestinal safety. Interestingly, parecoxib, a pro-drug of valdecoxib, is the only injecta...
Persistent Identifiers
free text keywords: Pharmacology, Drug Discovery, Cyclooxygenase, biology.protein, biology, Clinical pharmacology, law.invention, law, Etoricoxib, medicine.drug, medicine, Celecoxib, Valdecoxib, Parecoxib, Lumiracoxib, business.industry, business, Rofecoxib
Any information missing or wrong?Report an Issue